<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586258</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A03062-51</org_study_id>
    <secondary_id>2017-A03062-51</secondary_id>
    <nct_id>NCT03586258</nct_id>
  </id_info>
  <brief_title>Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage 2</brief_title>
  <acronym>CORAC2</acronym>
  <official_title>Anatomical Clinical Correlations. Neuropsychological and Brain Medical Imaging Study in Brain Damage Subjects 2 (CORAC2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two groups of subjects will be constitute: (i) patients with circumscribed brain injury
      (including stroke, vascular malformations, tumor or circumscribed infectious lesions) or
      degenerative/developmental disorders and selective cognitive disorders; (ii) healthy control
      subjects.

      The objective of this project is to evaluate specific neuropsychological deficits and apply
      current brain imaging techniques (anatomical, diffusion, functional, magnetic stimulation) to
      patients suffering from these cognitive deficits due to brain damage, in order to elucidate
      the brain mechanisms underlying these deficits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Deficit</measure>
    <time_frame>3 months to more than 2 years</time_frame>
    <description>The cognitive deficit of interest will depend on the localization of the brain lesion. The outcome measure could be a standardized neuropsychological test or an experimental test specifically elaborated for this protocol.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Cerebrovascular Disorders</condition>
  <condition>Brain Lesion</condition>
  <condition>Degenerative Disease</condition>
  <condition>Developmental Disability</condition>
  <arm_group>
    <arm_group_label>Brain Damaged Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Healthy Controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neuropsychological testing</intervention_name>
    <description>Experimental test about cognitive deficit of interest and standard neuropsychological tests</description>
    <arm_group_label>Brain Damaged Subjects</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain Imaging</intervention_name>
    <description>Anatomical, diffusion, and/or functional MRI</description>
    <arm_group_label>Brain Damaged Subjects</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Galvanic Vestibular Stimulation (GVS)</intervention_name>
    <description>Stimulation versus Sham</description>
    <arm_group_label>Brain Damaged Subjects</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 17 years

          -  French language

          -  Effective contraception for women during the study

          -  Informed consent

          -  No alcohol intake the day before the exam

          -  For patients only, focal cerebral lesion (stroke, malformation, tumor, inflammatory,
             infectious, traumatic), neonatal pathology, developmental or degenerative disease with
             cognitive deficit

        Exclusion Criteria:

          -  For healthy volunteers: previous neurological history (except non complicated migraine
             or epilepsy), previous psychiatric history (except depression with good evolution or
             anxiety), or severe cranial traumatism

          -  For patients: vigilance disorders, severe depression or anxiety.

          -  For both: psychotropic medication other than a hypnotic or an anxiolytic at low doses
             without dose modification for at least one month, severe visual or auditory
             impairment, patient without judicial or administrative liberty, measure of legal
             protection or no capable to express their consent, pregnancy or breastfeeding,
             contraindication for MRI or GVS if applicable, participation in another trial or
             former involvement in another trial within one month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier MARTINAUD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Caen University Hospital, Normandie UNIV, UNICAEN, PSL Research University, EPHE, Inserm, U1077, CHU de Caen, Neuropsychologie et Imagerie de la MÃ©moire Humaine, 14000 Caen, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier MARTINAUD, MD, PhD</last_name>
    <phone>2 31 06 46 17</phone>
    <phone_ext>+33</phone_ext>
    <email>martinaud-o@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MARTINAUD, MD, PhD</last_name>
      <phone>2 31 06 46 17</phone>
      <phone_ext>+33</phone_ext>
      <email>martinaud-o@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropsychological study</keyword>
  <keyword>Brain imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Developmental Disabilities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

